These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 27482815

  • 1. A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.
    Westbroek W, Nguyen M, Siebert M, Lindstrom T, Burnett RA, Aflaki E, Jung O, Tamargo R, Rodriguez-Gil JL, Acosta W, Hendrix A, Behre B, Tayebi N, Fujiwara H, Sidhu R, Renvoise B, Ginns EI, Dutra A, Pak E, Cramer C, Ory DS, Pavan WJ, Sidransky E.
    Dis Model Mech; 2016 Jul 01; 9(7):769-78. PubMed ID: 27482815
    [Abstract] [Full Text] [Related]

  • 2. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S, Schoenen FJ, Westbroek W, Zheng W, Sullivan P, Fujiwara H, Sidhu R, Khaliq ZM, Lopez GJ, Goldstein DS, Ory DS, Marugan J, Sidransky E.
    J Neurosci; 2016 Jul 13; 36(28):7441-52. PubMed ID: 27413154
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Validation of anti-glucocerebrosidase antibodies for western blot analysis on protein lysates of murine and human cells.
    Qi W, Davidson BA, Nguyen M, Lindstrom T, Grey RJ, Burnett R, Aflaki E, Sidransky E, Westbroek W.
    Biochem J; 2019 Jan 25; 476(2):261-274. PubMed ID: 30578288
    [Abstract] [Full Text] [Related]

  • 5. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J, Saftig P.
    J Neurochem; 2016 Oct 25; 139 Suppl 1():198-215. PubMed ID: 26860955
    [Abstract] [Full Text] [Related]

  • 6. Glucocerebrosidase and its relevance to Parkinson disease.
    Do J, McKinney C, Sharma P, Sidransky E.
    Mol Neurodegener; 2019 Aug 29; 14(1):36. PubMed ID: 31464647
    [Abstract] [Full Text] [Related]

  • 7. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
    Jung O, Patnaik S, Marugan J, Sidransky E, Westbroek W.
    Expert Rev Proteomics; 2016 May 29; 13(5):471-9. PubMed ID: 27098312
    [Abstract] [Full Text] [Related]

  • 8. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
    Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, Bu J, Sweet L, Passini MA, Dodge JC, Yu WH, Sidman RL, Cheng SH, Shihabuddin LS.
    Proc Natl Acad Sci U S A; 2013 Feb 26; 110(9):3537-42. PubMed ID: 23297226
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
    Atrian S, López-Viñas E, Gómez-Puertas P, Chabás A, Vilageliu L, Grinberg D.
    Proteins; 2008 Feb 15; 70(3):882-91. PubMed ID: 17803231
    [Abstract] [Full Text] [Related]

  • 11. Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.
    Burke DG, Rahim AA, Waddington SN, Karlsson S, Enquist I, Bhatia K, Mehta A, Vellodi A, Heales S.
    J Inherit Metab Dis; 2013 Sep 15; 36(5):869-72. PubMed ID: 23151684
    [Abstract] [Full Text] [Related]

  • 12. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.
    Kinghorn KJ, Grönke S, Castillo-Quan JI, Woodling NS, Li L, Sirka E, Gegg M, Mills K, Hardy J, Bjedov I, Partridge L.
    J Neurosci; 2016 Nov 16; 36(46):11654-11670. PubMed ID: 27852774
    [Abstract] [Full Text] [Related]

  • 13. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ.
    FEBS J; 2006 Sep 16; 273(17):4082-92. PubMed ID: 16934036
    [Abstract] [Full Text] [Related]

  • 14. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y, Sakamoto S, Kojima T, Homma M, Tanaka M, Matsui H.
    SLAS Discov; 2023 Oct 16; 28(7):344-349. PubMed ID: 37369311
    [Abstract] [Full Text] [Related]

  • 15. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration.
    Lunghi G, Carsana EV, Loberto N, Cioccarelli L, Prioni S, Mauri L, Bassi R, Duga S, Straniero L, Asselta R, Soldà G, Di Fonzo A, Frattini E, Magni M, Liessi N, Armirotti A, Ferrari E, Samarani M, Aureli M.
    Cells; 2022 Jul 29; 11(15):. PubMed ID: 35954187
    [Abstract] [Full Text] [Related]

  • 16. Measurement of GCase Activity in Cultured Cells.
    Shojima Y, Ogata J, Tsunemi T, Imai Y, Hattori N.
    Methods Mol Biol; 2021 Jul 29; 2322():47-52. PubMed ID: 34043191
    [Abstract] [Full Text] [Related]

  • 17. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
    Yang NY, Lee YN, Lee HJ, Kim YS, Lee SJ.
    Biol Chem; 2013 Jul 29; 394(7):807-18. PubMed ID: 23435096
    [Abstract] [Full Text] [Related]

  • 18. Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease.
    Peng Y, Liou B, Lin Y, Fannin V, Zhang W, Feldman RA, Setchell KDR, Grabowski GA, Sun Y.
    Cells; 2021 Sep 02; 10(9):. PubMed ID: 34571934
    [Abstract] [Full Text] [Related]

  • 19. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC, Krainc D.
    Mov Disord; 2016 Nov 02; 31(11):1610-1618. PubMed ID: 27619775
    [Abstract] [Full Text] [Related]

  • 20. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
    Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG.
    Int J Mol Sci; 2017 Feb 17; 18(2):. PubMed ID: 28218669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.